R 565 / NR565 Advanced
N
Pharmacology Final Exam Review
ACTUAL EXAM 2026/2027 |
Advanced Pharmacology Final
Review | Verified Q&A | Pass
Guaranteed - A+ Graded
=======================================================================
=
========
PART A – MULTIPLE CHOICE (Q1‑100)
========================================================================
========
* *Q1 (Pharmacokinetics – half-life):** A patient is started on a new medication with a half-life of
12 hours. Approximately how many days will it take to reach steady-state plasma
concentration?
A. 1 day
B. 2.5 days
C. 5 days
D. 7 days
* *[CORRECT]** B
*Rationale: Steady-state concentration is typically reached after 4-5 half-lives, which is the
standard pharmacokinetic principle for predicting drug accumulation. With a 12-hour half-life, 5
half-lives equal 60 hours or approximately 2.5 days, making this the most accurate estimate for
clinical practice. Option A (1 day) represents only 2 half-lives (25% accumulation), which is
insufficient for steady-state; Option C overestimates the timeframe; and Option D represents
nearly 14 half-lives, which is unnecessary for most medications. Clinical pearl: For drugs with
long half-lives (e.g., amiodarone, ~40 days), loading doses are often used to achieve
therapeutic effects sooner.*
,* *Q2 (Pharmacokinetics – first-pass effect):** Which of the following medications undergoes
significant first-pass hepatic metabolism, resulting in low oral bioavailability?
A. Nitroglycerin
B. Amlodipine
C. Metformin
D. Levothyroxine
* *[CORRECT]** A
*Rationale: Nitroglycerin undergoes extensive first-pass metabolism in the liver, with oral
bioavailability of less than 1%, which is why it is administered sublingually, transdermally, or
intravenously to bypass hepatic extraction. Amlodipine has high oral bioavailability (~64%)
despite some hepatic metabolism; metformin is not metabolized and has ~50-60%
bioavailability; levothyroxine is absorbed in the upper GI tract with approximately 80%
bioavailability. Clinical pearl: Always consider the route of administration for drugs with high
first-pass metabolism—sublingual nitroglycerin provides rapid onset (1-3 minutes) for acute
angina, while oral formulations are clinically ineffective.*
* *Q3 (Pharmacokinetics – CYP450 interactions):** A 68-year-old patient on warfarin (CYP2C9
substrate) is prescribed trimethoprim-sulfamethoxazole for a UTI. What is the primary concern?
A. Decreased warfarin absorption
B. Increased warfarin metabolism
C. Inhibition of CYP2C9 leading to increased INR
D. Induction of CYP3A4 causing warfarin resistance
* *[CORRECT]** C
*Rationale: Trimethoprim-sulfamethoxazole (TMP-SMX) is a potent inhibitor of CYP2C9, the
primary enzyme responsible for metabolizing the more active S-warfarin enantiomer, which can
increase warfarin plasma levels and INR by 50-100%. This interaction is well-documented in
FDA labeling and requires close INR monitoring (every 2-3 days) when TMP-SMX is prescribed.
Option A is incorrect because TMP-SMX does not affect warfarin absorption; Option B is wrong
because inhibition (not induction) occurs; Option D incorrectly identifies CYP3A4 as the relevant
enzyme. Clinical pearl: Other significant CYP2C9 inhibitors include amiodarone, fluconazole,
and metronidazole—always review medication lists for these interactions in patients on
warfarin.*
* *Q4 (Pharmacodynamics – receptor theory):** A drug that binds to a receptor and produces a
partial biological response even at full receptor occupancy is best described as a:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
**[CORRECT]** B
,* Rationale: A partial agonist binds to the receptor with high affinity but has lower intrinsic activity
compared to a full agonist, producing a submaximal response even when all receptors are
occupied—this is the fundamental definition in pharmacodynamic receptor theory.
Buprenorphine (partial mu-opioid agonist) and aripiprazole (partial D2 agonist) are classic
clinical examples. A full agonist (Option A) produces maximal response; a competitive
antagonist (Option C) binds without activating the receptor and blocks agonist effects; an
inverse agonist (Option D) produces opposite effects by stabilizing the inactive receptor
conformation. Clinical pearl: Partial agonists have a "ceiling effect" that can be advantageous for
safety—buprenorphine's partial agonism at mu-receptors reduces overdose risk compared to
full agonists like morphine.*
* *Q5 (Pharmacogenomics – CYP2D6):** A patient is a known CYP2D6 poor metabolizer. Which
medication would require the most significant dose adjustment or alternative selection?
A. Warfarin
B. Codeine
C. Atorvastatin
D. Lisinopril
* *[CORRECT]** B
*Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine for
analgesic effect; poor metabolizers experience minimal to no analgesia due to inadequate
morphine production, making this the most clinically significant interaction. The FDA issued a
boxed warning for codeine in CYP2D6 poor metabolizers, especially in children
post-tonsillectomy. Warfarin (Option A) is primarily metabolized by CYP2C9; atorvastatin
(Option C) by CYP3A4; and lisinopril (Option D) is not metabolized by CYP enzymes. Clinical
pearl: In CYP2D6 poor metabolizers, use morphine, hydromorphone, or oxycodone (partially
CYP2D6-dependent) instead of codeine or tramadol for pain management.*
* *Q6 (Pharmacogenomics – HLA-B*5701):** Before initiating abacavir in an HIV-positive patient,
which test is mandatory?
A. HLA-B*5701 screening
B. CYP2C19 genotyping
C. TPMT activity testing
D. G6PD level assessment
* *[CORRECT]** A
*Rationale: HLA-B*5701 screening is mandatory before abacavir initiation because carriers of
this allele have a significantly increased risk (up to 50%) of developing a potentially fatal
hypersensitivity reaction characterized by fever, rash, GI symptoms, and respiratory distress.
The FDA requires this testing on the abacavir label, and positive patients should never receive
abacavir. CYP2C19 genotyping (Option B) is relevant for clopidogrel and PPIs; TPMT testing
(Option C) for thiopurines; G6PD (Option D) for dapsone or primaquine. Clinical pearl: If
HLA-B*5701 testing is unavailable, do not prescribe abacavir—alternative NRTIs include
tenofovir or emtricitabine.*
, * *Q7 (Medication safety – Beers Criteria 2026):** According to the updated 2026 AGS Beers
Criteria, which medication is newly flagged with an increased caution recommendation in older
adults due to risks of respiratory depression and falls?
A. Diphenhydramine
B. Gabapentin
C. Metoprolol
D. Omeprazole
* *[CORRECT]** B
*Rationale: The 2026 AGS Beers Criteria update includes enhanced caution for gabapentinoids
(gabapentin and pregabalin) in older adults due to accumulating evidence of respiratory
depression risk (especially with opioids), falls, fractures, and cognitive impairment, even at
therapeutic doses. Diphenhydramine (Option A) has long been on the Beers list as a strong
anticholinergic; metoprolol (Option C) is not Beers-criteria inappropriate; omeprazole (Option D)
is flagged for C. difficile and fracture risk but not newly in 2026. Clinical pearl: When prescribing
gabapentinoids for neuropathic pain in older adults, start low (100mg TID), titrate slowly, and
reassess necessity at every visit due to the risk-benefit profile.*
* *Q8 (Medication safety – high-alert medications):** Which of the following is classified as a
high-alert medication by the Institute for Safe Medication Practices (ISMP) due to its narrow
therapeutic index?
A. Metformin
B. Insulin
C. Lisinopril
D. Sertraline
* *[CORRECT]** B
*Rationale: Insulin is classified as a high-alert medication by ISMP because dosing errors
(especially involving unit vs. mL confusion, or rapid-acting vs. long-acting mix-ups) can cause
severe hypoglycemia, seizures, coma, or death within hours. The narrow therapeutic index and
immediate physiological consequences make insulin one of the most dangerous medications in
clinical practice. Metformin (Option A) has a wide safety margin; lisinopril (Option C) and
sertraline (Option D) are not high-alert medications. Clinical pearl: Always use insulin pens with
distinct visual appearances, never abbreviate "units" as "U," and implement independent
double-checks for insulin administration in inpatient settings.*
* *Q9 (Medication safety – deprescribing):** A 78-year-old patient with advanced dementia,
multiple comorbidities, and limited life expectancy is taking donepezil 10mg daily. What is the
most appropriate deprescribing recommendation?
A. Continue indefinitely as it slows disease progression
B. Taper over 4-6 weeks to minimize cholinergic rebound
C. Stop abruptly since benefits are minimal in advanced disease
D. Increase to 23mg to maximize any remaining cognitive benefit
N
Pharmacology Final Exam Review
ACTUAL EXAM 2026/2027 |
Advanced Pharmacology Final
Review | Verified Q&A | Pass
Guaranteed - A+ Graded
=======================================================================
=
========
PART A – MULTIPLE CHOICE (Q1‑100)
========================================================================
========
* *Q1 (Pharmacokinetics – half-life):** A patient is started on a new medication with a half-life of
12 hours. Approximately how many days will it take to reach steady-state plasma
concentration?
A. 1 day
B. 2.5 days
C. 5 days
D. 7 days
* *[CORRECT]** B
*Rationale: Steady-state concentration is typically reached after 4-5 half-lives, which is the
standard pharmacokinetic principle for predicting drug accumulation. With a 12-hour half-life, 5
half-lives equal 60 hours or approximately 2.5 days, making this the most accurate estimate for
clinical practice. Option A (1 day) represents only 2 half-lives (25% accumulation), which is
insufficient for steady-state; Option C overestimates the timeframe; and Option D represents
nearly 14 half-lives, which is unnecessary for most medications. Clinical pearl: For drugs with
long half-lives (e.g., amiodarone, ~40 days), loading doses are often used to achieve
therapeutic effects sooner.*
,* *Q2 (Pharmacokinetics – first-pass effect):** Which of the following medications undergoes
significant first-pass hepatic metabolism, resulting in low oral bioavailability?
A. Nitroglycerin
B. Amlodipine
C. Metformin
D. Levothyroxine
* *[CORRECT]** A
*Rationale: Nitroglycerin undergoes extensive first-pass metabolism in the liver, with oral
bioavailability of less than 1%, which is why it is administered sublingually, transdermally, or
intravenously to bypass hepatic extraction. Amlodipine has high oral bioavailability (~64%)
despite some hepatic metabolism; metformin is not metabolized and has ~50-60%
bioavailability; levothyroxine is absorbed in the upper GI tract with approximately 80%
bioavailability. Clinical pearl: Always consider the route of administration for drugs with high
first-pass metabolism—sublingual nitroglycerin provides rapid onset (1-3 minutes) for acute
angina, while oral formulations are clinically ineffective.*
* *Q3 (Pharmacokinetics – CYP450 interactions):** A 68-year-old patient on warfarin (CYP2C9
substrate) is prescribed trimethoprim-sulfamethoxazole for a UTI. What is the primary concern?
A. Decreased warfarin absorption
B. Increased warfarin metabolism
C. Inhibition of CYP2C9 leading to increased INR
D. Induction of CYP3A4 causing warfarin resistance
* *[CORRECT]** C
*Rationale: Trimethoprim-sulfamethoxazole (TMP-SMX) is a potent inhibitor of CYP2C9, the
primary enzyme responsible for metabolizing the more active S-warfarin enantiomer, which can
increase warfarin plasma levels and INR by 50-100%. This interaction is well-documented in
FDA labeling and requires close INR monitoring (every 2-3 days) when TMP-SMX is prescribed.
Option A is incorrect because TMP-SMX does not affect warfarin absorption; Option B is wrong
because inhibition (not induction) occurs; Option D incorrectly identifies CYP3A4 as the relevant
enzyme. Clinical pearl: Other significant CYP2C9 inhibitors include amiodarone, fluconazole,
and metronidazole—always review medication lists for these interactions in patients on
warfarin.*
* *Q4 (Pharmacodynamics – receptor theory):** A drug that binds to a receptor and produces a
partial biological response even at full receptor occupancy is best described as a:
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Inverse agonist
**[CORRECT]** B
,* Rationale: A partial agonist binds to the receptor with high affinity but has lower intrinsic activity
compared to a full agonist, producing a submaximal response even when all receptors are
occupied—this is the fundamental definition in pharmacodynamic receptor theory.
Buprenorphine (partial mu-opioid agonist) and aripiprazole (partial D2 agonist) are classic
clinical examples. A full agonist (Option A) produces maximal response; a competitive
antagonist (Option C) binds without activating the receptor and blocks agonist effects; an
inverse agonist (Option D) produces opposite effects by stabilizing the inactive receptor
conformation. Clinical pearl: Partial agonists have a "ceiling effect" that can be advantageous for
safety—buprenorphine's partial agonism at mu-receptors reduces overdose risk compared to
full agonists like morphine.*
* *Q5 (Pharmacogenomics – CYP2D6):** A patient is a known CYP2D6 poor metabolizer. Which
medication would require the most significant dose adjustment or alternative selection?
A. Warfarin
B. Codeine
C. Atorvastatin
D. Lisinopril
* *[CORRECT]** B
*Rationale: Codeine is a prodrug that requires CYP2D6-mediated conversion to morphine for
analgesic effect; poor metabolizers experience minimal to no analgesia due to inadequate
morphine production, making this the most clinically significant interaction. The FDA issued a
boxed warning for codeine in CYP2D6 poor metabolizers, especially in children
post-tonsillectomy. Warfarin (Option A) is primarily metabolized by CYP2C9; atorvastatin
(Option C) by CYP3A4; and lisinopril (Option D) is not metabolized by CYP enzymes. Clinical
pearl: In CYP2D6 poor metabolizers, use morphine, hydromorphone, or oxycodone (partially
CYP2D6-dependent) instead of codeine or tramadol for pain management.*
* *Q6 (Pharmacogenomics – HLA-B*5701):** Before initiating abacavir in an HIV-positive patient,
which test is mandatory?
A. HLA-B*5701 screening
B. CYP2C19 genotyping
C. TPMT activity testing
D. G6PD level assessment
* *[CORRECT]** A
*Rationale: HLA-B*5701 screening is mandatory before abacavir initiation because carriers of
this allele have a significantly increased risk (up to 50%) of developing a potentially fatal
hypersensitivity reaction characterized by fever, rash, GI symptoms, and respiratory distress.
The FDA requires this testing on the abacavir label, and positive patients should never receive
abacavir. CYP2C19 genotyping (Option B) is relevant for clopidogrel and PPIs; TPMT testing
(Option C) for thiopurines; G6PD (Option D) for dapsone or primaquine. Clinical pearl: If
HLA-B*5701 testing is unavailable, do not prescribe abacavir—alternative NRTIs include
tenofovir or emtricitabine.*
, * *Q7 (Medication safety – Beers Criteria 2026):** According to the updated 2026 AGS Beers
Criteria, which medication is newly flagged with an increased caution recommendation in older
adults due to risks of respiratory depression and falls?
A. Diphenhydramine
B. Gabapentin
C. Metoprolol
D. Omeprazole
* *[CORRECT]** B
*Rationale: The 2026 AGS Beers Criteria update includes enhanced caution for gabapentinoids
(gabapentin and pregabalin) in older adults due to accumulating evidence of respiratory
depression risk (especially with opioids), falls, fractures, and cognitive impairment, even at
therapeutic doses. Diphenhydramine (Option A) has long been on the Beers list as a strong
anticholinergic; metoprolol (Option C) is not Beers-criteria inappropriate; omeprazole (Option D)
is flagged for C. difficile and fracture risk but not newly in 2026. Clinical pearl: When prescribing
gabapentinoids for neuropathic pain in older adults, start low (100mg TID), titrate slowly, and
reassess necessity at every visit due to the risk-benefit profile.*
* *Q8 (Medication safety – high-alert medications):** Which of the following is classified as a
high-alert medication by the Institute for Safe Medication Practices (ISMP) due to its narrow
therapeutic index?
A. Metformin
B. Insulin
C. Lisinopril
D. Sertraline
* *[CORRECT]** B
*Rationale: Insulin is classified as a high-alert medication by ISMP because dosing errors
(especially involving unit vs. mL confusion, or rapid-acting vs. long-acting mix-ups) can cause
severe hypoglycemia, seizures, coma, or death within hours. The narrow therapeutic index and
immediate physiological consequences make insulin one of the most dangerous medications in
clinical practice. Metformin (Option A) has a wide safety margin; lisinopril (Option C) and
sertraline (Option D) are not high-alert medications. Clinical pearl: Always use insulin pens with
distinct visual appearances, never abbreviate "units" as "U," and implement independent
double-checks for insulin administration in inpatient settings.*
* *Q9 (Medication safety – deprescribing):** A 78-year-old patient with advanced dementia,
multiple comorbidities, and limited life expectancy is taking donepezil 10mg daily. What is the
most appropriate deprescribing recommendation?
A. Continue indefinitely as it slows disease progression
B. Taper over 4-6 weeks to minimize cholinergic rebound
C. Stop abruptly since benefits are minimal in advanced disease
D. Increase to 23mg to maximize any remaining cognitive benefit
